Literature DB >> 16101514

Delivering RNA interference to the mammalian brain.

Timothy M Fountaine1, Matthew J A Wood, Richard Wade-Martins.   

Abstract

RNA interference (RNAi) is a new modality in gene therapy which can elicit down-regulation of gene expression and has enormous potential in the treatment of neurological diseases. RNAi is a conserved system through which double stranded RNA (dsRNA) guides sequence specific mRNA degradation. The RNAi apparatus may be artificially triggered by delivery of naked siRNA molecules or by plasmid-based expression of dsRNA. Before these techniques can be used as effective treatments in the brain, efficient methods of in vivo delivery must be devised. This review first describes the mechanism of RNAi, and then critically examines both viral and non-viral methods for delivery of RNAi to the mammalian brain. There have been a number of important recent publications in this field and the progress towards effective in vivo delivery of RNAi to the central nervous system is discussed. Finally, potential problems that must be considered before applying this technology to the human brain are outlined.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16101514     DOI: 10.2174/1566523054546206

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  14 in total

Review 1.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 2.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

3.  CCN4 regulates vascular smooth muscle cell migration and proliferation.

Authors:  Hao Liu; Wenpeng Dong; Zhiqi Lin; Jingbo Lu; Heng Wan; Zhongxin Zhou; Zhengjun Liu
Journal:  Mol Cells       Date:  2013-06-25       Impact factor: 5.034

4.  Attenuated Salmonella choleraesuis-mediated RNAi targeted to conserved regions against foot-and-mouth disease virus in guinea pigs and swine.

Authors:  Wei Cong; Hong Jin; Chengda Jiang; Weiyao Yan; Mingqiu Liu; Jiulian Chen; Xiaoping Zuo; Zhaoxin Zheng
Journal:  Vet Res       Date:  2010-01-13       Impact factor: 3.683

5.  Development of a targeted siRNA delivery system using FOL-PEG-PEI conjugate.

Authors:  Bijesh K Biswal; Niladri B Debata; Rama S Verma
Journal:  Mol Biol Rep       Date:  2009-10-09       Impact factor: 2.316

6.  Interplay of beta2* nicotinic receptors and dopamine pathways in the control of spontaneous locomotion.

Authors:  Maria Elena Avale; Philippe Faure; Stéphanie Pons; Patricia Robledo; Thierry Deltheil; Denis J David; Alain M Gardier; Rafael Maldonado; Sylvie Granon; Jean-Pierre Changeux; Uwe Maskos
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-02       Impact factor: 11.205

7.  NLRP3 is Required for Complement-Mediated Caspase-1 and IL-1beta Activation in ICH.

Authors:  Sheng-Tao Yao; Fang Cao; Jia-Lin Chen; Wei Chen; Rui-Ming Fan; Gang Li; You-Chao Zeng; Song Jiao; Xiang-Ping Xia; Chong Han; Qi-Shan Ran
Journal:  J Mol Neurosci       Date:  2016-12-08       Impact factor: 3.444

Review 8.  MicroRNA and brain tumors: a cause and a cure?

Authors:  Saroj P Mathupala; Sandeep Mittal; Murali Guthikonda; Andrew E Sloan
Journal:  DNA Cell Biol       Date:  2007-05       Impact factor: 3.311

9.  Laser-evoked synaptic transmission in cultured hippocampal neurons expressing channelrhodopsin-2 delivered by adeno-associated virus.

Authors:  Jennifer Wang; Mazahir T Hasan; H Sebastian Seung
Journal:  J Neurosci Methods       Date:  2009-06-26       Impact factor: 2.390

10.  Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth.

Authors:  Laurence Crombez; May Catherine Morris; Sandrine Dufort; Gudrun Aldrian-Herrada; Quan Nguyen; Gary Mc Master; Jean-Luc Coll; Frederic Heitz; Gilles Divita
Journal:  Nucleic Acids Res       Date:  2009-05-29       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.